New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Christopher Soo

Dr Christopher Soo

ADHD in Children – Practical Advice and Update for GPs

Prof Rod Baber

Prof Rod Baber

Oral vs Transdermal MHT – Which Option for Who?

Prof Jason Ong

Prof Jason Ong

The Mpox Emergency – What You Need to Know

Dr Janet Green

Dr Janet Green

Infant and Specialty Formula – What’s in Them and Why

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 1 January 1970